Olomoucine and Roscovitine are pharmacological inhibitors of cyclin-dependent kinases
(CDK) displaying a promising profile as anticancer agents. Both compounds are effective …

Olomoucine and Roscovitine are two ATP-competing compounds described as specific
inhibitors of cyclin-dependent kinases (CDK). Both drugs showed to induce apoptosis in SH …

Cyclin-dependent kinases (CDKs) have recently raised considerable interest in view of their
key role in the regulation of the cell cycle progression. In proliferating cells, distinct CDKs …

Escape from the proper control of the cell cycle by up-regulation of cyclins or aberrant
activation of cyclin-dependent kinases (CDKs) as well as by inactivation of cellular inhibitors …

Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs
in the context of new cancer therapies. Roscovitine and related compounds, like seliciclib …

Inhibition of cyclin‐dependent kinases (CDKs) is a novel strategy in the therapy of human
malignancies. The pharmacological CDK inhibitors representing a few distinct classes of …

The effect of the cyclin-dependent (CDK) inhibitors olomoucine and roscovitine on cell
kinetics was studied. To this end, nonsmall cell lung cancer (NSCLC) cell line MR65 and …

Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer
agents usually target several CDKs in cells. Some of them are also able to increase cellular …

The aim of this study was to compare the effect of two related CDK inhibitors: roscovitine
(ROSC) and olomoucine (OLO) on the cell cycle progression in human breast cancer MCF-7 …

Neuroblastoma (NB), the most frequent extracranial solid tumor of children accounting for
nearly 15% of all childhood cancer mortality, displays overexpression of antiapoptotic Bcl-2 …